OTCMLEXTF
Market cap734kUSD
Dec 24, Last price
0.02USD
1D
7.19%
1Q
-72.67%
IPO
-87.81%
Name
Lexston Life Sciences Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-868k
L-21.74%
CFO
-523k
L-47.03%
Profile
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | |
| Income | |||||
Revenues | 361 142.11% | ||||
Cost of revenue | 554 | 790 | 2,048 | ||
Unusual Expense (Income) | |||||
NOPBT | (554) | (790) | (1,687) | ||
NOPBT Margin | |||||
Operating Taxes | 143 | 321 | |||
Tax Rate | |||||
NOPAT | (554) | (933) | (2,008) | ||
Net income | (868) -21.74% | (1,109) -52.21% | (2,320) 164.83% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 402 | 908 | 1,153 | ||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (390) | (511) | (619) | ||
| Cash flow | |||||
Cash from operating activities | (523) | (988) | (1,401) | ||
CAPEX | (200) | (434) | |||
Cash from investing activities | (200) | (110) | |||
Cash from financing activities | 603 | 908 | 1,153 | ||
FCF | (583) | (971) | (2,148) | ||
| Balance | |||||
Cash | 390 | 511 | 590 | ||
Long term investments | 1 | 1 | 29 | ||
Excess cash | 390 | 511 | 601 | ||
Stockholders' equity | 711 | 803 | 2,670 | ||
Invested Capital | 321 | 292 | 272 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 31,891 | 28,580 | 11,162 | ||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (528) | (760) | (1,655) | ||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||